[1] ADAM R D, CORIU D, JERCAN A, et al. Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature[J]. ESC Heart Fail, 2021,8(4):2380-2396.
[2] GARCIA-PAVIA P, RAPEZZI C, ADLER Y, et al. Diagnosis and treatment of cardiac amyloidosis. a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases[J]. Eur J Heart Fail, 2021, 23(4):512-526.
[3] FALK R H. Cardiac amyloidosis: a treatable disease, often overlooked[J]. Circulation, 2011, 124(9):1079-1085.
[4] BERNARDI L, PASSINO C, PORTA C, et al. Widespread cardiovascular autonomic dysfunction in primary amyloidosis: does spontaneous hyperventilation have a compensatory role against postural hypotension?[J]. Heart, 2002,88(6):615-621.
[5] GONZALEZ-LOPEZ E, GAGLIARDI C, DOMINGUEZ F, et al.Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths[J]. Eur Heart J, 2017,38(24):1895-1904.
[6] ESCHER F, SENONER M, DOERLER J, et al. When and how do patients with cardiac amyloidosis die?[J]. Clin Res Cardiol, 2020, 109(1):78-88.
[7] HASSERJIAN R P, GOODMAN H J B, LACHMANN H J, et al. Bone marrow findings correlate with clinical outcome in systemic AL amyloidosis patients[J]. Histopathology, 2007,50(5):567-573.
[8] MUCHTAR E, BUADI F K, DISPENZIERI A, et al. Immunoglobulin light-chain amyloidosis: from basics to new developments in diagnosis, prognosis and therapy[J]. Acta Haematol, 2016, 135(3):172-190.
[9] NIENHUIS H L A, BIJZET J, HAZENBERG B P C. The prevalence and management of systemic amyloidosis in western countries[J]. Kidney Dis: Basel, 2016,2(1):10-19.
[10] SPERRY B W,VRANIAN M N,HACHAMOVITCH R,et al.Are classic predictors of voltage valid in cardiac amyloidosis?A contemporary analysis of electrocardiographic findings[J]. Int J Cardiol,2016,214:477-481.
[11] CYRILLE N B,GOLDSMITH J,ALVAREZ J,et al.Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis[J]. Am J Cardiol,2014,114(7):1089-1093.
[12] MUSSINELLI R, SALINARO F, ALOGNA A, et al. Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis[J]. Ann Noninvasive Electrocardiol, 2013, 18(3):271-280.
[13] MOHTY D, DAMY T, COSNAY P, et al. Cardiac amyloidosis: updates in diagnosis and management[J]. Arch Cardiovasc Dis, 2013, 106(10):528-540.
[14] MARTINEZ-NAHARRO A, TREIBEL T A, ABDEL-GADIR A,et al. Magnetic resonance in transthyretin cardiac amyloidosis[J]. J Am Coll Cardiol, 2017, 70(4):466-477.
[15] BONDERMAN D, PÖLZL G, ABLASSER K, et al. Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement[J]. Wien Klin Wochenschr, 2020,132(23/24):742-761.
[16] PALLADINI G, RUSSO P, BOSONI T, et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine[J]. Clin Chem, 2009, 55(3):499-504. |
